<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066660</url>
  </required_header>
  <id_info>
    <org_study_id>HiQ-FUCO-003</org_study_id>
    <nct_id>NCT04066660</nct_id>
  </id_info>
  <brief_title>Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hi-Q Marine Biotech International, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hi-Q Marine Biotech International, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, controlled trial was conducted evaluating the efficacy of&#xD;
      Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy&#xD;
      in patients with metastatic colorectal cancer. The previous study results demonstrate the&#xD;
      advantages of Oligo-Fucoidan in improving the disease control rate. The previous study might&#xD;
      provide insights into the development of cancer treatments, particularly in the combination&#xD;
      of natural or herbal products with chemotarget agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oligo-Fucoidan, a heparin-like molecule with high percentages of L-fucose and sulfated ester&#xD;
      groups and low percentages of D-xylose, D-galactose, D-mannose, and glucuronic acid, was&#xD;
      present in the cell wall matrix of brown seaweed. Brown seaweed Oligo-Fucoidan was reported&#xD;
      to demonstrate various biological activities such as antioxidant, anti-inflammatory,&#xD;
      antiproliferative, and proapoptotic activities. Oligo-Fucoidan was also revealed to inhibit&#xD;
      the growth of breast and lung cancers in animal models. Oligo-Fucoidan treatment induces the&#xD;
      degradation of transforming growth factor (TGF)-β receptor and the consequent inhibition of&#xD;
      the epithelial-mesenchymal transition (EMT) in cancer cells. In addition to these molecular&#xD;
      mechanisms, it is imperative to investigate the potential of Oligo-Fucoidan as a miRNA&#xD;
      regulator for breast cancer treatment and thus delineate the molecular mechanisms underlying&#xD;
      the anticancer effects of Oligo-Fucoidan. A randomized, double-blind, controlled trial was&#xD;
      conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500&#xD;
      to 800 Da. as a supplemental therapy in patients with metastatic colorectal cancer. The&#xD;
      previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease&#xD;
      control rate. The previous study might provide insights into the development of cancer&#xD;
      treatments, particularly in the combination of natural or herbal products with chemotarget&#xD;
      agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>from Day 1 to end of treatment (4th visit, month 6)</time_frame>
    <description>Disease Control Rate will be evaluated by RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Screening (baseline), complete of Treatment Phase(month 6), and 2 months, 6 months, 12 months and 18 months post-treatment follow up</time_frame>
    <description>Objective Response Rate will be evaluated using measurements according to RECISTversion 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>Screening (baseline), complete of Treatment Phase(month 6), and 2 months, 6 months, 12 months and 18 months post-treatment follow up</time_frame>
    <description>Overall Survival Rate will be evaluated using measurements according to RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Screening (baseline), complete of Treatment Phase(month 6), and 2 months, 6 months, 12 months and 18 months post-treatment follow up</time_frame>
    <description>Progression Free Survival will be evaluated using measurements according to RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>1st visit to 4th visit (from day 1 to month 6)</time_frame>
    <description>Quality of Life will be evaluated by questionnaire based on EORTC-QLQ30, specific questions evaluated by scores from 1 (not at all), 2 (a little), 3 (quite a bit), 4 (very much); overall healthy and quality of life will be evalauted by scores from 1 (very poor) to 7 (excellent)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment &amp; Oligo Fucoidan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.4 g Oligo Fucoidan powder by six months, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4.4 g Placebo powder by six months, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligo Fucoidan</intervention_name>
    <description>4.4 g oligo fucoidan powder, oral, BID</description>
    <arm_group_label>Treatment &amp; Oligo Fucoidan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4.4 g placebo powder, oral, BID</description>
    <arm_group_label>Treatment &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years;&#xD;
&#xD;
          -  ECOG PS 0-2;&#xD;
&#xD;
          -  Histologically or cytologically documented unresectable HCC;&#xD;
&#xD;
          -  Measurable disease by RECIST criteria;&#xD;
&#xD;
          -  Previous local therapy completed &gt; 6 weeks;&#xD;
&#xD;
          -  Any acute toxicity (CTC-AE) &lt; grade 1;&#xD;
&#xD;
          -  Child-Pugh A-B&#xD;
&#xD;
          -  Albumin ≥ 2.8 g/dl;&#xD;
&#xD;
          -  Serum total bilirubin ≤ 3 mg/dl;&#xD;
&#xD;
          -  INR ≤ 2.3 or PT ≤ 6 seconds above control;&#xD;
&#xD;
          -  WBC ≥ 3,000/µl;&#xD;
&#xD;
          -  ANC ≥ 1,500/µl;&#xD;
&#xD;
          -  Platelets ≥ 60,000/µl;&#xD;
&#xD;
          -  Hb ≥ 8.5 g/dl;&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN; AND&#xD;
&#xD;
          -  Amylase and lipase &lt; 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic tumors;&#xD;
&#xD;
          -  Prior or concomitant systemic anti-cancer treatment for HCC, including:&#xD;
&#xD;
          -  Systemic chemotherapy (TACE is allowed)&#xD;
&#xD;
          -  Immunotherapy&#xD;
&#xD;
          -  Farnesyltransferase inhibitors&#xD;
&#xD;
          -  VEGF/VEGFR- inhibitors or other anti-angiogenesis agents&#xD;
&#xD;
          -  Investigational anti-cancer agents&#xD;
&#xD;
          -  Severe and/or uncontrolled medical conditions:&#xD;
&#xD;
          -  Uncontrolled high blood pressure&#xD;
&#xD;
          -  History of poor compliance with anti-hypertensive agents&#xD;
&#xD;
          -  Active or uncontrolled infection&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  CHF&#xD;
&#xD;
          -  MI or CVA &lt; 6 months&#xD;
&#xD;
          -  GI bleeding &lt; 30 days&#xD;
&#xD;
          -  Unable to take oral medications&#xD;
&#xD;
          -  Severe renal impairment which requires dialysis; proteinuria &gt; grade 2;&#xD;
&#xD;
          -  BMT or stem cell rescue &lt; 4 months; organ transplant;&#xD;
&#xD;
          -  HIV infection;&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury &lt; 4 weeks or&#xD;
             those who receive minor surgical procedures (e.g. core biopsy or fine needle&#xD;
             aspiration) within 2 weeks;&#xD;
&#xD;
          -  Patients taking narrow therapeutic index medications will be monitored closely. These&#xD;
             include warfarin, phenytoin, quinidine, carbamazepine, phenobarbital, cyclosporine,&#xD;
             and digoxin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xizhong Shen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qunyan Yao, PhD</last_name>
    <phone>86-13661696668</phone>
    <email>yao.qunyan@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qunyan Yao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xizhong Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.zs-hospital.sh.cn/</url>
    <description>Fudan University Zhongshan Hospital</description>
  </link>
  <results_reference>
    <citation>Tsai HL, Tai CJ, Huang CW, Chang FR, Wang JY. Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. Mar Drugs. 2017 Apr 21;15(4). pii: E122. doi: 10.3390/md15040122.</citation>
    <PMID>28430159</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligo Fucoidan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fucoidan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

